Pancreatic Cancer Research

ResearcherGuiyang Medical UniversityActive in the last 2 years

Chao Yu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9244-9416; OpenAlex author ID A5056581550, A5121400467. Sources: OpenAlex.

Their work

Papers
25 (first author 1, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
46
Papers, trials and grants by year

2014: 3 papers · 2015: 4 papers · 2016: 2 papers · 2017: 1 paper · 2018: 2 papers · 2019: 2 papers · 2020: 1 paper · 2021: none · 2022: 3 papers · 2023: 2 papers · 2024: 2 papers · 2025: 3 papers

Papers 25

  1. CDCA7 enhances STAT3 transcriptional activity to regulate aerobic glycolysis and promote pancreatic cancer progression and gemcitabine resistance. Last author DOI 10.1038/s41419-025-07399-1↗
  2. ENO1-mediated deoxycytidine synthesis and gemcitabine resistance by stabilizing RRM2 in pancreatic cancer. Last author DOI 10.1038/s41419-025-08061-6↗
  3. EIF4E-mediated biogenesis of circPHF14 promotes the growth and metastasis of pancreatic ductal adenocarcinoma via Wnt/β-catenin pathway. Co-author DOI 10.1186/s12943-025-02262-5↗
  4. Endosomal Trafficking Bypassed by the RAB5B-CD109 Interplay Promotes Axonogenesis in KRAS-Mutant Pancreatic Cancer. Co-author DOI 10.1002/advs.202405092↗
  5. Transcription factor KLF9 inhibits the proliferation, invasion, and migration of pancreatic cancer cells by repressing KIAA1522. Co-author DOI 10.1111/ajco.14048↗
  6. FOXQ1 promotes pancreatic cancer cell proliferation, tumor stemness, invasion and metastasis through regulation of LDHA-mediated aerobic glycolysis. Last author DOI 10.1038/s41419-023-06207-y↗
  7. RNF7 Facilitated the Tumorigenesis of Pancreatic Cancer by Activating PI3K/Akt Signaling Pathway. Last author DOI 10.1155/2023/1728463↗
  8. RHBDL2 promotes the proliferation, migration, and invasion of pancreatic cancer by stabilizing the N1ICD via the OTUD7B and activating the Notch signaling path… Last author DOI 10.1038/s41419-022-05379-3↗
  9. The Senescence-Related Signature Predicts Prognosis and Characterization of Tumor Microenvironment Infiltration in Pancreatic Cancer. Last author DOI 10.1155/2022/1916787↗
  10. MICAL1 facilitates pancreatic cancer proliferation, migration, and invasion by activating WNT/β-catenin pathway. Last author DOI 10.1186/s12967-022-03749-1↗
  11. MiR-137 promotes anoikis through modulating the AKT signaling pathways in Pancreatic Cancer. Co-author DOI 10.7150/jca.44037↗
  12. LAMB3 mediates apoptotic, proliferative, invasive, and metastatic behaviors in pancreatic cancer by regulating the PI3K/Akt signaling pathway. Co-author DOI 10.1038/s41419-019-1320-z↗
  13. MicroRNA-137 reduces stemness features of pancreatic cancer cells by targeting KLF12. Co-author DOI 10.1186/s13046-019-1105-3↗
  14. MiR-1297 suppresses pancreatic cancer cell proliferation and metastasis by targeting MTDH. Co-author DOI 10.1016/j.mcp.2018.06.003↗
  15. Oncogenic TRIM31 confers gemcitabine resistance in pancreatic cancer via activating the NF-κB signaling pathway. Co-author DOI 10.7150/thno.23259↗
  16. miR-138-5p suppresses autophagy in pancreatic cancer by targeting SIRT1. Co-author DOI 10.18632/oncotarget.14360↗
  17. TRIM37 promoted the growth and migration of the pancreatic cancer cells. Co-author DOI 10.1007/s13277-015-4078-7↗
  18. Tumor suppressor Fbxw7 antagonizes WNT signaling by targeting β-catenin for degradation in pancreatic cancer. Co-author DOI 10.1007/s13277-016-5217-5↗
  19. MicroRNA-138-5p regulates pancreatic cancer cell growth through targeting FOXC1. Co-author DOI 10.1007/s13402-014-0200-x↗
  20. MiR-1181 inhibits stem cell-like phenotypes and suppresses SOX2 and STAT3 in human pancreatic cancer. Co-author DOI 10.1016/j.canlet.2014.11.007↗
  21. Reduction of miR-29c enhances pancreatic cancer cell migration and stem cell-like phenotype. First author DOI 10.18632/oncotarget.3089↗
  22. Upregulation of microRNA‑138‑5p inhibits pancreatic cancer cell migration and increases chemotherapy sensitivity. Co-author DOI 10.3892/mmr.2015.4031↗
  23. KAP-1 is overexpressed and correlates with increased metastatic ability and tumorigenicity in pancreatic cancer. Co-author DOI 10.1007/s12032-014-0025-5↗
  24. MicroRNA-100 regulates pancreatic cancer cells growth and sensitivity to chemotherapy through targeting FGFR3. Co-author DOI 10.1007/s13277-014-2271-8↗
  25. microRNA-137 modulates pancreatic cancer cells tumor growth, invasion and sensitivity to chemotherapy. Co-author PMID 25550779↗

Closest collaborators

The 25 strongest of 46 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhiwei He · 8 shared papers, 2019–2025 · strength 1.38
  2. Dijie Zheng · 4 shared papers, 2022–2025 · strength 0.86
  3. Chengyi Sun · 10 shared papers, 2014–2020 · strength 0.85
  4. Shiyu Chen · 5 shared papers, 2018–2023 · strength 0.70
  5. Jianxin Jiang · 11 shared papers, 2014–2019 · strength 0.70
  6. Cheng-Yi Sun · 3 shared papers, 2022–2024 · strength 0.63
  7. Hao Hua · 3 shared papers, 2022–2023 · strength 0.60
  8. She Tian · 5 shared papers, 2016–2024 · strength 0.59
  9. Rufu Chen · 2 shared papers, 2024–2025 · strength 0.49
  10. Zhuo Kui Wu · 2 shared papers, 2024–2025 · strength 0.49
  11. Zhou Fang · 2 shared papers, 2024–2025 · strength 0.49
  12. Changhao Wu · 2 shared papers, 2023–2025 · strength 0.46
  13. Kun Cai · 2 shared papers, 2022 · strength 0.35
  14. Meiyuan Chen · 5 shared papers, 2015–2016 · strength 0.33
  15. Liangtang Zeng · 1 shared paper, 2025 · strength 0.30
  16. Shi Zuo · 1 shared paper, 2024 · strength 0.26
  17. Yuting Guo · 1 shared paper, 2024 · strength 0.26
  18. Futang Li · 1 shared paper, 2025 · strength 0.26
  19. Xinghao Sun · 1 shared paper, 2025 · strength 0.26
  20. Yongning Li · 1 shared paper, 2025 · strength 0.26
  21. Min Wang · 5 shared papers, 2014–2015 · strength 0.24
  22. Xingjun Guo · 3 shared papers, 2015–2019 · strength 0.24
  23. Yaozhen Pan · 3 shared papers, 2014–2019 · strength 0.23
  24. Jian Zheng · 1 shared paper, 2023 · strength 0.22
  25. Changhao Chen · 1 shared paper, 2024 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.